63
CanSino Biologics, which is testing a COVID-19 vaccine on human subjects, surged 87 percent on its first trading day on the Shanghai STAR Market on Thursday.
The company’s shares closed at 393.11 yuan (US$56.20) in its STAR debut, with an intraday high of 477 yuan. Its market value reached 97.3 billion yuan after the market closed on Thursday, ranking it No. 6 in terms of valuation on the Nasdaq-style innovation board.
Founded in Tianjin in 2009, CanSino has more than 450 employees. Approved vaccine for the Ebola virus and 16 vaccine candidates in the product pipeline, according to the company’s website.
Read more at Shanghai Daily
